Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC).

Next Previous
Trial Profile

Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PADIMAC

Most Recent Events

  • 25 Jun 2017 Primary endpoint (2-year PFS for patients who, having achieved CR/VGPR following PAD therapy, do not receive any further treatment) has not been met, according to the abstract presented at the 22nd Congress of the European Haematology Association.
  • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
  • 02 Apr 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top